IPF-Related Cough

Trial Objective

IPF-Related CoughThe purpose of this study is to evaluate the efficacy of an investigational study drug called RVT-1601 for treatment of persistent cough in patients with Idiopathic Pulmonary Fibrosis (IP) and to understand the impact on patients’ cough symptoms over time.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults over 40 years of age with IPF and persistent cough for a minimum of 8 weeks.

Age: 40-89    Gender: Any Gender

Estimated Time Commitment

12 clinic visits over 7 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kaitlin Fier

Kaitlin Fier

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Respivant Sciences

Principal Investigators


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More